The D4Z4caster DNA methylation signature identifies individuals at epigenetic risk for facioscapulohumeral muscular dystrophy

D4Z4 DNA methylation signature by targeted NGS bisulfite sequencing, FSHD epigenetic diagnosis on blood and saliva

D4Z4caster is an epigenetic diagnostic tool using targeted NGS bisulfite sequencing to quantify DNA methylation at the D4Z4 locus, identifying individuals at epigenetic risk for FSHD. Validated on saliva and blood, it distinguishes FSHD1 (D4Z4 contraction) from FSHD2 (SMCHD1 variants), is low-cost, and scalable to high throughput. D4Z4caster addresses the complexity of conventional FSHD diagnosis, which often fails to confirm genetically in clinically evident patients, enabling direct epigenetic profile interpretation.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

FSHD diagnosis remains challenging in practice, particularly for index cases with low D4Z4 repeat count or FSHD2. An NGS bisulfite tool applicable on saliva represents a significant advance for family cascade screening and resource-limited settings. Worth monitoring for clinical laboratory validation.

Clinical impact: 2/3 · Evidence strength: 3/3 · Novelty: 2/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 8/10